Russian biopharmaceutical company "Satereks," specializing in the development of innovative drugs for the treatment of diabetes and metabolic syndrome, the University of California at San Diego (USA), Biopharmcluster “Severny” of the Moscow Institute of Physics and Technology and the Research Institute "KhimRar" (CDRI) signed an agreement to conduct joint research on the development of innovative drugs for the treatment of type 2 diabetes mellitus (T2DM).
The partnership involves conducting translational research for the development of molecule - innovative non-systemic agonists of TGR-5 receptors obtained by MIPT scientists, Satereks and CDRI using specific pharmacological models of the University of California at San Diego.
Using the experience and expertise of Professor Olefsky, Head of the Department of Endocrinology and Metabolism at the University of California at San Diego, in collaboration with Russia's leading institution of higher education - MIPT, and the University of California at San Diego, the company "Satereks" will contribute to the introduction of safe and efficient anti-diabetic medicines of a new generation to the pharmaceutical market.
More about the partners:
The Company "Satereks" – a pharmaceutical company, established in 2010 at the Centre for High Technology "KhimRar." The company is engaged in a wide range of pharmaceutical developments of promising new compounds from high-throughput screening, medicinal chemistry and the early stages of pre-clinical development, pre-full scale clinical trials and registration of innovative medicines for the treatment of type-2 diabetes and metabolic syndrome. www.satrx.ru
University of California, San Diego - a research university located in San Diego, California, USA - one of the ten campuses of the University of California. Founded in 1960 near the Scripps Institution of Oceanography. The University provides undergraduate training in 125 specialties and 52 in master’s. The University is working with the Medical Center of San Diego and with a number of regional centers of excellence such as: the Salk Institute, the Sanford-Burnham Medical Research Institute, and The Scripps Research Institute. The University has eight Nobel Prize winners, three laureates of the U.S. National Science Medal and a Pulitzer Prize winner. The University was admitted to the Association of American Universities in 1982. www.ucsd.edu
Moscow Institute of Physics and Technology (State University) is the leading institution of higher education of the Russian Federation, training highly qualified specialists in different fields of modern science and technology. The Institute has a rich history. Its founders and employees were Nobel Prize Laureates P.L. Kapitsa, N.N. Semenov, and L.D. Landau. Nobel Prize winners have also been among its graduates. Many MIPT professors are leading Russian scientists. Among them, more than 80 academicians and corresponding members of the Russian Academy of Sciences. Since its founding, MIPT has used an original system of training, widely known as "the Phystech System", which combines fundamental education and engineering disciplines with student research work. www.mipt.ru
Biopharmklaster "Severny" - the merger of the Moscow Physical-Technical Institute with small innovative companies, research organizations, industrial companies, carried out with the support of the Ministry of Industry and Trade of the Russian Federation, the Moscow region, the City Dolgoprudnyi and Khimki. BFC "Severny" is focused on the creation of a belt around MIPT of small innovative enterprises and corporate laboratories in the field of living systems. In the structure of CBF "Severny", in addition to MIPT, are included the Fund "Skolkovo", the Center for High Technology "KhimRar," the Company "Akrikhin" GC "Protek", JSC "Geropharm", FSUE RPC "Pharmzaschita" the Company "Altonika», Quantum Pharmaceuticals and others. www.pharmcluster.ru
Research Institute "KhimRar" (CDRI) - the largest private research center that performs contract work in the field of pre-clinical and clinical studies of innovative medicines and the development of laboratory and pilot scale production of synthetic regulations and biotechnological products for domestic and foreign pharmaceutical companies. The Institute focuses on the creation of innovative new medicines and topical therapeutic areas, using the highest scientific potential and experience of Russian scientists in the development of solutions that are integrated into the framework of a broad research platform based on the latest world achievements. www.iihr.ru